ClinicalTrials.gg

Program

Cyclophosphamide

Also written as “cyclophosphamide”, “Cyclophosphamide,Fludarabine” and “Cytoxan”.

Its studies are mostly in Breast Neoplasms · Multiple Myeloma · Lymphoma, Large B-Cell, Diffuse · Leukemia, Lymphocytic, Chronic, B-Cell · Carcinoma, Non-Small-Cell Lung, led by 28 companies.

Furthest: phase 4, since Jan 4, 201170 company-led studies, 25 open or runningNext primary completion: Jan 14, 2027 (early phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hoffmann-La Roche151 open or runningphase 4since Jan 4, 2011Oct 16, 2007Feb 28, 2028phase 2 · NCT04931342
Beijing Biotech99 open or runningphase 2since Apr 5, 2026Mar 14, 2026Feb 18, 2027phase 1 · NCT07480941
ImmunoVaccine Technologies, Inc. (IMV Inc.)63 open or runningphase 2since Dec 12, 2014Dec 12, 2014none ahead
Amgen40 open or runningphase 2since Jul 5, 2000Jul 5, 2000none ahead
Sanofi40 open or runningphase 3since Jul 11, 2001Jul 11, 2001none ahead
Takeda41 open or runningphase 2since Jul 25, 2007Jul 25, 2007none ahead
Allogene Therapeutics32 open or runningphase 2since Dec 8, 2022Dec 8, 2022Dec 2027phase 2 · NCT06500273
Bristol-Myers Squibb21 open or runningphase 2since Dec 22, 2016Dec 22, 2016Mar 15, 2029phase 1 · NCT07115745
hangzhou-huasai-biomedicine-co-ltd22 open or runningphase 1since Jul 22, 2025Jul 22, 2025Aug 30, 2027phase 1 · NCT07105176
rampart-health-l-l-c21 open or runningphase 2since Aug 9, 2019Aug 9, 2019none ahead
shanghai-first-song-biotechnology-co-ltd21 open or runningearly phase 1since Jul 30, 2024Jul 30, 2024none ahead
adicet-therapeutics10 open or runningphase 1since Jan 26, 2021Jan 26, 2021none ahead
aryogen-pharmed-co10 open or runningphase 3since Nov 21, 2017Nov 21, 2017none ahead
caribou-biosciences-inc11 open or runningphase 1since Nov 16, 2020Nov 16, 2020none ahead
carsgen-therapeutics-co-ltd10 open or runningphase 1since Aug 9, 2016Aug 9, 2016none ahead
criterium-inc10 open or runningphase 1since Aug 7, 2012Aug 7, 2012none ahead
Gilead Sciences10 open or runningphase 1since Oct 13, 2017Oct 13, 2017none ahead
Merck10 open or runningphase 2since Oct 23, 2008Oct 23, 2008none ahead
Merck KGaA, Darmstadt, Germany10 open or runningphase 1since Oct 11, 2012Oct 11, 2012none ahead
neukio-biotherapeutics-shanghai-co-ltd11 open or runningearly phase 1since Aug 19, 2025Aug 19, 2025Jan 14, 2027early phase 1 · NCT07144462
nkarta-inc11 open or runningphase 1since Sep 25, 2020Sep 25, 2020none ahead
Oncotherapeutics10 open or runningphase 2since Jul 30, 2014Jul 30, 2014none ahead
precision-biosciences-inc10 open or runningphase 2since Jul 19, 2019Jul 19, 2019none ahead
Sangamo Therapeutics10 open or runningphase 2since Aug 22, 2014Aug 22, 2014none ahead
Sarah Cannon Research Institute10 open or runningphase 2since Jun 27, 2007Jun 27, 2007none ahead
seah-lim-m-d10 open or runningphase 2since Aug 29, 2012Aug 29, 2012none ahead
shanghai-unicar-therapy-bio-medicine-technology-co-ltd11 open or runningphase 1since Mar 28, 2021Mar 28, 2021none ahead
tty-biopharm10 open or runningphase 2since Aug 31, 2010Aug 31, 2010none ahead

Also a collaborator on its studies: Natera, Incyte, AbbVie and Johnson & Johnson.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 40 studies since Oct 16, 2007.

  1. Feb 7, 2022Phase 2 study in Platinum-resistant Epithelial Ovarian CancerImmunoVaccine Technologies, Inc. (IMV Inc.) · NCT05243524 · 16 enrolled · United States, Canada, Puerto Rico
  2. Dec 8, 2022Allogene Therapeutics's first study: phase 2 study in RecurrenceNew to Allogene TherapeuticsAllogene Therapeutics · NCT05714345 · 2 enrolled · United States, Belgium
  3. Jan 4, 2023Phase 2 study in LymphomaTakeda · NCT05673785 · 52 enrolled · China
  4. Jun 26, 2024Phase 2 study in Lymphoma, Large B-Cell, DiffuseAllogene Therapeutics · NCT06500273 · 250 planned · United States, Australia, Canada and more
  5. Jul 30, 2024shanghai-first-song-biotechnology-co-ltd's first studies: 2 early phase 1 studiesNew to shanghai-first-song-biotechnology-co-ltdshanghai-first-song-biotechnology-co-ltd · NCT06532643, NCT06532630
  6. Feb 7, 2025Phase 1 study in Autoimmune DiseasesBristol-Myers Squibb · NCT07115745 · 125 planned · United States, Australia, Brazil and more
  7. Jul 8, 2025Phase 1 study in Lupus Erythematosus, SystemicAllogene Therapeutics · NCT07085104 · 66 planned · United States, Canada
  8. Jul 22, 2025hangzhou-huasai-biomedicine-co-ltd's first study: phase 1 study in Advanced Non-Small Cell Lung CancerNew to hangzhou-huasai-biomedicine-co-ltdhangzhou-huasai-biomedicine-co-ltd · NCT07105176 · 12 planned · China
  9. Aug 19, 2025neukio-biotherapeutics-shanghai-co-ltd's first study: early phase 1 study in AutoimmuneNew to neukio-biotherapeutics-shanghai-co-ltdneukio-biotherapeutics-shanghai-co-ltd · NCT07144462 · 8 planned · China
  10. Mar 14, 2026Beijing Biotech's first studies: 2 phase 1 studiesNew to Beijing BiotechBeijing Biotech · NCT07480941, NCT07492628
  11. Apr 5, 20263 phase 2 studiesPhase 2 reachedBeijing Biotech · NCT07523542, NCT07523529, NCT07551362
  12. Apr 18, 2026Phase 1 study in GliomaBeijing Biotech · NCT07551336 · 36 planned · China
  13. May 14, 20263 phase 2 studiesBeijing Biotech · NCT07598955, NCT07617805, NCT07617753
  14. Sep 15, 2026Phase 1 study in Advanced NSCLChangzhou-huasai-biomedicine-co-ltd · NCT07830342 · 24 planned · China

Ahead

  1. Jan 14, 2027Primary completion: early phase 1 study in Autoimmuneneukio-biotherapeutics-shanghai-co-ltd · NCT07144462
  2. Feb 18, 2027Primary completion: phase 1 study in GlioblastomaBeijing Biotech · NCT07480941
  3. Mar 14, 2027Primary completion: phase 2 study in RecurrenceBeijing Biotech · NCT07617805
  4. Mar 14, 2027Primary completion: phase 2 study in Stomach NeoplasmsBeijing Biotech · NCT07551362

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

The newest 60 of 70 led by companies developing it. Each opens its study page. Every study on its drug page →

StudyPhaseStatusLed byPrimary completionSize
NCT07830342Advanced NSCLC · China1Recruitinghangzhou-huasai-biomedicine-co-ltdOct 202824
NCT07617805Recurrence · China2RecruitingBeijing BiotechMar 14, 202742
NCT07617753Carcinoma, Ovarian Epithelial · China2RecruitingBeijing BiotechJun 14, 202736
NCT07598955Thymoma · China2RecruitingBeijing BiotechJun 14, 202736
NCT07551362Stomach Neoplasms · China2RecruitingBeijing BiotechMar 14, 202736
NCT07551336Glioma · China1RecruitingBeijing BiotechApr 14, 202736
NCT07523542Lupus Erythematosus, Systemic · China2RecruitingBeijing BiotechMar 14, 202724
NCT07523529Neoplasm Metastasis · China2RecruitingBeijing BiotechApr 14, 202772
NCT07492628Urinary Bladder Neoplasms · China1RecruitingBeijing BiotechJun 14, 202742
NCT07480941Glioblastoma · China1RecruitingBeijing BiotechFeb 18, 202736
NCT07144462Autoimmune · ChinaEarly 1Recruitingneukio-biotherapeutics-shanghai-co-ltdJan 14, 20278
NCT07105176Advanced Non-Small Cell Lung Cancer · China1Recruitinghangzhou-huasai-biomedicine-co-ltdAug 30, 202712
NCT07085104Lupus Erythematosus, Systemic · United States, Canada1RecruitingAllogene TherapeuticsFeb 202866
NCT07115745Autoimmune Diseases · United States, Australia, Brazil and more1RecruitingBristol-Myers SquibbMar 15, 2029125
NCT06532643Lymphoma · ChinaEarly 1UNKNOWNshanghai-first-song-biotechnology-co-ltdSep 1, 20259
NCT06532630B-Cell Malignancy · ChinaEarly 1Recruitingshanghai-first-song-biotechnology-co-ltdSep 1, 20259
NCT06500273Lymphoma, Large B-Cell, Diffuse · United States, Australia, Canada and more2RecruitingAllogene TherapeuticsDec 2027250
NCT05673785Lymphoma · China2Active, not recruitingTakedaApr 27, 202552
NCT05714345Recurrence · United States, Belgium2TerminatedAllogene TherapeuticsFeb 20, 20242
NCT05243524Platinum-resistant Epithelial Ovarian Cancer · United States, Canada, Puerto Rico2TerminatedImmunoVaccine Technologies, Inc. (IMV Inc.)Jul 24, 202316
NCT04931342Ovarian Neoplasms · United States, Australia, Canada and more2Active, not recruitingHoffmann-La RocheFeb 28, 2028176
NCT04920617Lymphoma, Large B-Cell, Diffuse · United States, Australia, Canada and more2RecruitingImmunoVaccine Technologies, Inc. (IMV Inc.)Oct 2024102
NCT04825496Recurrence · China1Recruitingshanghai-unicar-therapy-bio-medicine-technology-co-ltdDec 31, 202318
NCT04790903Lymphoma, Large B-Cell, Diffuse · United States, France, Italy and more1TerminatedHoffmann-La RocheMay 21, 202450
NCT04735471Lymphoma, Follicular · United States1Terminatedadicet-therapeuticsFeb 3, 202534
NCT04713371Neoplasm Metastasis · United States2Active, not recruitingrampart-health-l-l-cDec 202432
NCT04637763Lymphoma, Non-Hodgkin · United States, Australia, Israel1Active, not recruitingcaribou-biosciences-incSep 11, 202572
NCT04623944Leukemia, Myeloid, Acute · United States1Active, not recruitingnkarta-incOct 2, 202461
NCT04090775Metastatic Prostatic Adenocarcinoma · United States2Completedrampart-health-l-l-cJul 30, 202012
NCT04030195Lymphoma, Non-Hodgkin · United States2Completedprecision-biosciences-incJun 24, 202118
NCT03836352Ovarian Neoplasms · United States, Canada2Active, not recruitingImmunoVaccine Technologies, Inc. (IMV Inc.)Dec 31, 2023184
NCT03425656Breast Neoplasms · Iran, Islamic Republic of3Completedaryogen-pharmed-coMar 6, 2018108
NCT03332576Carcinoma, Ovarian Epithelial · United States, Canada1CompletedImmunoVaccine Technologies, Inc. (IMV Inc.)Sep 8, 201637
NCT03318861Multiple Myeloma · United States1TerminatedGilead SciencesDec 17, 201817
NCT03003520Lymphoma, Large B-Cell, Diffuse · United States, Austria, Denmark and more2CompletedBristol-Myers SquibbApr 24, 202246
NCT02876978Lung Squamous Cell Carcinoma · China1UNKNOWNcarsgen-therapeutics-co-ltdOct 201720
NCT02785250Carcinoma, Ovarian Epithelial · United States, Canada2Active, not recruitingImmunoVaccine Technologies, Inc. (IMV Inc.)Oct 202085
NCT02693210Arthritis, Rheumatoid · Australia, Belgium, Canada and more2CompletedHoffmann-La RocheAug 2002161
NCT02605915Breast Neoplasms · United States1CompletedHoffmann-La RocheNov 13, 201998
NCT02533401Leukemia, Lymphocytic, Chronic, B-Cell · Argentina, Venezuela2CompletedHoffmann-La RocheDec 201434
NCT02419742Breast Neoplasms · India4CompletedHoffmann-La RocheJun 24, 2021110
NCT02323230Lymphoma, Large B-Cell, Diffuse · Canada2TerminatedImmunoVaccine Technologies, Inc. (IMV Inc.)Jun 20174
NCT02225665Acquired Immunodeficiency Syndrome · United States2CompletedSangamo TherapeuticsJun 20188
NCT02206425Multiple Myeloma · United States2CompletedOncotherapeuticsJan 19, 201845
NCT02055820Lymphoma, Non-Hodgkin · United States, Australia, Austria and more2CompletedHoffmann-La RocheJun 28, 2017267
NCT01980589Multiple Myeloma · United States1CompletedAmgenMar 201622
NCT01731587Carcinoma, Non-Small-Cell Lung1WithdrawnMerck KGaA, Darmstadt, Germany0
NCT01679041Multiple Sclerosis · United States2Terminatedseah-lim-m-dNov 20131
NCT01660750Multiple Myeloma · United States1Completedcriterium-incAug 201529
NCT01649856Lymphoma, Large B-Cell, Diffuse · Algeria, Argentina, Belgium and more3CompletedHoffmann-La RocheOct 21, 2014572
NCT01292603Leukemia, Lymphocytic, Chronic, B-Cell · Argentina, Australia, Brazil and more1CompletedHoffmann-La RocheMay 7, 2014240
NCT01283386Leukemia, Lymphocytic, Chronic, B-Cell · Russian Federation4TerminatedHoffmann-La RocheMar 16, 201626
NCT01271010Leukemia, Lymphocytic, Chronic, B-Cell · Russian Federation4TerminatedHoffmann-La RocheMay 4, 201689
NCT01263704Leukemia, Lymphocytic, Chronic, B-Cell · Israel2CompletedHoffmann-La RocheApr 3, 201742
NCT01210768Breast Neoplasms · Taiwan2UNKNOWNtty-biopharmOct 31, 2022254
NCT00779129Breast Neoplasms2CompletedMerckAug 200770
NCT00773695Breast Neoplasms · Norway2CompletedHoffmann-La RocheNov 9, 2022150
NCT00718549Leukemia, Lymphocytic, Chronic, B-Cell · Belarus, Poland3CompletedHoffmann-La RocheSep 14, 2015128
NCT00715208Lymphoma, Follicular · United States, Puerto Rico2CompletedTakedaFeb 201155
NCT00545714Leukemia, Lymphocytic, Chronic, B-Cell · Spain2CompletedHoffmann-La RocheMay 20, 201686

How it is read

Names in the registry

  • “Cyclophosphamide”, 74 entries
  • “cyclophosphamide”, 9 entries
  • “Cyclophosphamide,Fludarabine”, 4 entries
  • “Cytoxan”, 3 entries
  • “CHOP”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.